Taking people in United StatesNo phase
Inspire UAS High Apnea Hypopnea Index (AHI)/High Body Mass Index (BMI) Post-Approval Study
Key facts
- Who runs it
- Inspire Medical Systems, Inc.
- Where
- Bradenton, Chicago, Colorado Springs, Kansas City, and Rochester, United StatesSee the 5 sites
- Trial code
- Status
- Recruiting
- People taking part
- 70 people, planned
- Started
- 31 Jul 2025
- Expected to end
- 1 Jan 2032
- Type of study
- Observational, 2 groups
- Treatments tested
- Inspire® UAS System
- Record updated
- 27 March 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Subject is at least 18 years of age
- Subject has a diagnosis of severe OSA (65 ≤ AHI ≤ 100) based on a recent sleep study (within 12 months) OR Subject has a diagnosis of moderate to severe OSA (15≤AHI≤100) AND a baseline Body Mass Index of 32<BMI≤40 kg/m2
- Subject has documented failure of, or intolerance to, positive airway pressure treatments (such as CPAP or BPAP machines; NOTE: PAP failure is defined as an inability to eliminate OSA (AHI > 15 despite PAP usage). PAP intolerance is defined as the inability to use PAP (> 5 nights per week, 4 hours of usage per night) or unwillingness to use PAP (e.g. patient returns the PAP system after attempting to use it)
- Subject is willing and able to have stimulation hardware permanently implanted and to use the patient remote to activate the stimulation
- Subject is willing and able to return for follow-up visits, undergo sleep studies (including in-lab and at-home), and complete questionnaires related to the study
- Subject is willing and able to provide informed consent
Who cannot take part
- Subject has any condition or procedure that has compromised neurological control of the upper airway
- Subject has a terminal illness with life expectancy < 12 months
- Subject has a combination of central + mixed apneas > 25% of the total apnea-hypopnea index (AHI) based on a recent sleep study (within 12 months)
- Subject has any anatomical finding that would compromise the performance of upper airway stimulation, such as the presence of complete concentric collapse of the soft palate
- Subject is unable or does not have the necessary assistance to operate the patient remote
- Subject is pregnant or plans to become pregnant
- Subject has an implantable device that may be susceptible to unintended interaction with the Inspire System
- Any other reason the investigator deems the subject is unfit for participation in the study
Where in United States
- Florida Sleep SpecialistsBradenton, United StatesContact: Barbara JohnsTaking people
- Rush University Medical CenterChicago, United StatesContact: Mahendra ShahTaking people
- Colorado ENT & AllergyColorado Springs, United StatesContact: Monica DavisTaking people
- University of Kansas Medical CenterKansas City, United StatesContact: Bryan HumphreyTaking people
- University of RochesterRochester, United StatesContact: Paul AllenTaking people
About the trial
What the trial wants to find out
The purpose of this observational clinical study is to provide evaluation of long-term safety and effectiveness in a newly expanded patient population including patients with a higher AHI and a higher BMI.
The 2 groups in the trial
- High AHI
Following patients with 65\<AHI≤100 events/hr after Inspire Implantation for a period of 5 years
Treatment: Inspire® UAS System
- High BMI
Following patients with 32\<BMI≤40 kg/m2 after Inspire Implantation for a period of 5 years
Treatment: Inspire® UAS System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Inspire UAS High AHI/High BMI Post-Approval Study
- Record updated
- 27 March 2026